{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:07:05Z","timestamp":1774408025158,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Maraviroc, a noncompetitive antagonist of the CCR5 coreceptor, was recently approved in the USA as a treatment of HIV infection. For antiretroviral agents that target the virus, antiviral effect can be related to some extent to plasma drug concentrations. For CCR5 antagonists that target the host cells, receptor occupancy <jats:italic>in vivo<\/jats:italic> might be a better predictor of efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>To develop a population pharmacokinetic (PK)\u2013pharmacodynamic (PD) model that describes CCR5 receptor occupancy by maraviroc after oral administration at different doses in healthy volunteers and HIV\u2010positive patients and to assess the relevance of receptor occupancy in predicting the decrease in viral load (HIV\u20101 RNA copies\u2003ml<jats:sup>\u22121<\/jats:sup>) in HIV\u2010positive patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Receptor occupancy data from 88 individuals enrolled in two multiple dose trials were included in the population PK\u2013receptor binding model. Out of the 88 individuals, 25 were HIV\u20101\u2010infected patients and had viral load measurements, whereas the remaining 63 were healthy volunteers. Doses ranged from 3\u2003mg b.i.d. to 600\u2003mg q.d. A previously published PK\u2013PD disease model describing the effect of maraviroc on the viral load was updated by replacing its PD module by the receptor occupancy model. Simulated viral load\u2013time profiles with the updated model were compared with the profiles observed in patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The majority of measured plasma concentrations were associated with receptor occupancy \u226550% even at the lowest dose of 3\u2003mg b.i.d. A simple direct <jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub> model appeared to describe satisfactorily the PK\u2013receptor occupancy relationship. The estimated <jats:italic>K<\/jats:italic><jats:sub><jats:italic>D<\/jats:italic><\/jats:sub> was around 0.0894\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>, far below the operational <jats:italic>in vivo<\/jats:italic> antiviral IC<jats:sub>50<\/jats:sub> of 8\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>. Accordingly, simulations led to marked overprediction of the decrease in viral load\u2013time profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Maraviroc receptor occupancy close to the maximum is required to induce a significant decrease in viral load, indicating that <jats:italic>in vivo<\/jats:italic> CCR5 receptor occupancy by maraviroc is not a direct measure of drug inhibitory activity. Considering the imprecision of the measurement in the upper flat part of the maraviroc concentration <jats:italic>vs.<\/jats:italic> percent CCR5 occupancy curve, it can reasonably be concluded that routine monitoring of receptor occupancy as a biomarker for maraviroc efficacy will not be helpful. Based on this analysis, it was decided not to use receptor occupancy as a biomarker of viral load inhibition during the development of CCR5 antagonist compounds.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2008.03140.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T04:04:35Z","timestamp":1205208275000},"page":"86-94","source":"Crossref","is-referenced-by-count":38,"title":["Population pharmacokinetic\/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV\u2010positive patients"],"prefix":"10.1111","volume":"65","author":[{"given":"Maria C.","family":"Rosario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Jacqmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pat","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elna","family":"Van Der Ryst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1319"},{"key":"e_1_2_7_3_2","first-page":"F","article-title":"In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti\u2010HIV activity","volume":"43","author":"Dorr PK","year":"2003","journal-title":"Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_2_7_4_2","unstructured":"PullenS SaleH NapierC MansfieldR HolbrookM.Maraviroc is a slowly reversible antagonist at the human CCR5 in a CRE luciferase reporter gene assay (abstract 504). In:13th Conference on Retroviruses and Opportunistic Infections. 2006 February 5\u20138; Denver CO."},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_2_7_6_2","unstructured":"DorrP MacartneyM RickettG Smith\u2010BurchnellC DobbsS MoriJ GriffenP LokJ IrvineR WestbyM HitchcockC StammenB PriceD ArmourD WoodA PerrosM. UK\u2010427\u2003857 a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5 (abstract 12). In:10th Conference on Retroviruses and Opportunistic Infections. 2003 February 10\u201314; Boston MA."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.010"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000220021.64115.37"},{"key":"e_1_2_7_9_2","volume-title":"NONMEM User's Guide","author":"Beal SL","year":"1992"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03139.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03141.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03140.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03140.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:27:01Z","timestamp":1694615221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03140.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,10]]},"references-count":10,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03140.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03140.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,10]]}}}